Lawrence Steinman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lawrence Steinman has a total of 784 co-authors. Here are the top co-authors by number of shared publications:
Peggy P. Ho
Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Beckman Center for Molecular Medicine, Stanford, CA 94305
13 shared publications- William H. Robinson
Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
13 shared publications Raymond A. Sobel
Department of Pathology, Stanford University School of Medicine, Palo Alto Veterans Affairs Health Care System, CA
12 shared publicationsJonathan B. Rothbard
Department of Neurology and Neurological Sciences, Stanford University, CA; and
11 shared publications- Scott S. Zamvil
Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco
9 shared publications Michael P. Kurnellas
Alector, South San Francisco, California 94080
7 shared publications
Latest Publications
- Open Access
Genetic Disruption at the CIP2A Locus Modulates T Cell Responses and Attenuates Experimental Autoimmune Encephalomyelitis
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) driven by pathogenic T cell-mediated inflammation. Fingolimod (FTY720), an approved therapy for MS, is an established activator of protein phosphatase 2A (PP2A). However the contribution of PP2A in autoimmune neuroinflammation remains incompletely understood. Here, we addressed this question using experimental autoimmune encephalomyelitis (EAE), a murine model of MS, in mice carrying a genetic disruption of the locus encoding cancerous inhibitor of protein phosphatase 2A (CIP2A), an endogenous inhibitor of PP2A. Mice with disruption of the CIP2A locus, the knock out (KO) mice, exhibited attenuated EAE severity compared with wild-type (WT) controls. Histological and flow-cytometric analyses revealed markedly reduced infiltration of mononuclear cells, including CD4 + and CD4 + CXCR6 + encephalitogenic T cells, in the CNS of diseased KO mice. Reduced numbers of these T cell populations were also observed in peripheral lymphoid organs of the Cip2a-deficient mice during EAE, while T cell abundance was comparable under steady-state conditions, suggesting impaired activation-induced expansion rather than altered homeostasis or migration. Single-cell RNA sequencing of CNS and lymph node immune cells revealed changes in cell-type abundance and gene expression. Notably, Il17a expression was reduced in CNS CD8+ T cells and showed a similar trend in γδ T cells. Together, our findings reveal that genetic disruption at the CIP2A locus attenuates EAE, possibly by limiting the expansion and accumulation of encephalitogenic T cell populations in CNS. These results identify the CIP2A locus as a previously unrecognized regulator of T cell-driven autoimmune neuroinflammation and provide new insights into mechanisms that restrain pathogenic T cell responses during EAE.
Open AccessGenetic Disruption at the CIP2A Locus Modulates T Cell Responses and Attenuates Experimental Autoimmune Encephalomyelitis
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) driven by pathogenic T cell-mediated inflammation. Fingolimod (FTY720), an approved therapy for MS, is an established activator of protein phosphatase 2A (PP2A). However the contribution of PP2A in autoimmune neuroinflammation remains incompletely understood. Here, we addressed this question using experimental autoimmune encephalomyelitis (EAE), a murine model of MS, in mice carrying a genetic disruption of the locus encoding cancerous inhibitor of protein phosphatase 2A (CIP2A), an endogenous inhibitor of PP2A. Mice with disruption of the CIP2A locus, the knock out (KO) mice, exhibited attenuated EAE severity compared with wild-type (WT) controls. Histological and flow-cytometric analyses revealed markedly reduced infiltration of mononuclear cells, including CD4 + and CD4 + CXCR6 + encephalitogenic T cells, in the CNS of diseased KO mice. Reduced numbers of these T cell populations were also observed in peripheral lymphoid organs of the Cip2a-deficient mice during EAE, while T cell abundance was comparable under steady-state conditions, suggesting impaired activation-induced expansion rather than altered homeostasis or migration. Single-cell RNA sequencing of CNS and lymph node immune cells revealed changes in cell-type abundance and gene expression. Notably, Il17a expression was reduced in CNS CD8+ T cells and showed a similar trend in γδ T cells. Together, our findings reveal that genetic disruption at the CIP2A locus attenuates EAE, possibly by limiting the expansion and accumulation of encephalitogenic T cell populations in CNS. These results identify the CIP2A locus as a previously unrecognized regulator of T cell-driven autoimmune neuroinflammation and provide new insights into mechanisms that restrain pathogenic T cell responses during EAE.
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (5) , e200625
“Home”
- 1 September 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (5) , e200625
Open Access“Home”
- Open Access
- 19 May 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 46 (1)
C1-esterase Inhibitor Treatment is Associated with Immune and Vascular Pathway Modulation in PASC with Neurological Symptoms: Longitudinal Plasma Proteomics
Post-acute sequelae of SARS-CoV-2 infection (PASC), particularly neurological manifestations, remain a significant therapeutic challenge, likely driven by persistent inflammation, immune dysregulation, and endothelial dysfunction. In a randomized, double-blind, placebo-controlled crossover trial, 10 patients with post-COVID-19 neurological symptoms received C1-esterase inhibitor (C1-INH; RUCONEST®) or placebo over two eight-week phases. Longitudinal plasma proteomics (SomaScan®) profiled molecular dynamics during and after C1-INH treatment. C1-INH administration was associated with distinct, phase-specific proteomic signatures, including lower levels of inflammatory-associated proteins such as CRP and IL-6, increased levels of neuroimmune and endothelial repair proteins (Neuropilin-2, CD83, C1QTNF5), and modulation of bradykinin-kinin and extracellular matrix pathways. These molecular shifts were evaluated in relation to clinical change scores during the active treatment windows. Several proteomic changes were observed at timepoint 26 after treatment cessation, describing candidate post-treatment molecular trajectories. In conclusion, these results provide exploratory mechanistic insights and support the need for validation in larger, prospective cohorts. Together, these findings prioritize immune and vascular pathways for further investigation in PASC and may have relevance to other post-infectious neuroimmune conditions.
- 19 May 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 46 (1)
Open AccessC1-esterase Inhibitor Treatment is Associated with Immune and Vascular Pathway Modulation in PASC with Neurological Symptoms: Longitudinal Plasma Proteomics
Post-acute sequelae of SARS-CoV-2 infection (PASC), particularly neurological manifestations, remain a significant therapeutic challenge, likely driven by persistent inflammation, immune dysregulation, and endothelial dysfunction. In a randomized, double-blind, placebo-controlled crossover trial, 10 patients with post-COVID-19 neurological symptoms received C1-esterase inhibitor (C1-INH; RUCONEST®) or placebo over two eight-week phases. Longitudinal plasma proteomics (SomaScan®) profiled molecular dynamics during and after C1-INH treatment. C1-INH administration was associated with distinct, phase-specific proteomic signatures, including lower levels of inflammatory-associated proteins such as CRP and IL-6, increased levels of neuroimmune and endothelial repair proteins (Neuropilin-2, CD83, C1QTNF5), and modulation of bradykinin-kinin and extracellular matrix pathways. These molecular shifts were evaluated in relation to clinical change scores during the active treatment windows. Several proteomic changes were observed at timepoint 26 after treatment cessation, describing candidate post-treatment molecular trajectories. In conclusion, these results provide exploratory mechanistic insights and support the need for validation in larger, prospective cohorts. Together, these findings prioritize immune and vascular pathways for further investigation in PASC and may have relevance to other post-infectious neuroimmune conditions.
- Open Access
- 11 May 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (20)
Peripheral complement C4 protein in schizophrenia: Association with gene copy number and immune cell subtypes
The lack of highly effective disease-modifying treatments for schizophrenia necessitates exploration of novel aspects of its pathophysiology, including attention to innate immune mechanisms outside the brain. C4 protein activation, associated with the complement cascade of innate immunity, associates with symptoms and predicts outcomes in schizophrenia. However, C4 protein activation does not coincide with expected changes to other proteins in the complement cascade, suggesting another source of C4 protein activation. Studying a combination of fresh whole blood from 10 anonymous donors and a large set of publicly available microarray data, we show that C4 protein is found and expressed primarily in neutrophils and monocytes. Then, we compared the correlation between C4 protein in neutrophils, classical monocytes, plasma, and the number of C4A gene copies. We determined the number of C4A genes using digital droplet PCR, C4 protein in neutrophils (15 patients/21 controls) and plasma (30 patients/38 controls) using Western blotting, and classical monocytes (30 patients/38 controls) using flow cytometry. We found a large positive correlation between the number of C4A gene copies and the amount of C4 protein only in neutrophils and only in the schizophrenia group (Spearman’s rho = 0.63, 95% BCa CI: 0.12 to 0.89, P = 0.012). Our results indicate a convergence of innate immunity mechanisms associated with schizophrenia. The involvement of innate immunity deserves further attention to determine whether it could be a target for therapy in schizophrenia.
- 11 May 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (20)
Open AccessPeripheral complement C4 protein in schizophrenia: Association with gene copy number and immune cell subtypes
The lack of highly effective disease-modifying treatments for schizophrenia necessitates exploration of novel aspects of its pathophysiology, including attention to innate immune mechanisms outside the brain. C4 protein activation, associated with the complement cascade of innate immunity, associates with symptoms and predicts outcomes in schizophrenia. However, C4 protein activation does not coincide with expected changes to other proteins in the complement cascade, suggesting another source of C4 protein activation. Studying a combination of fresh whole blood from 10 anonymous donors and a large set of publicly available microarray data, we show that C4 protein is found and expressed primarily in neutrophils and monocytes. Then, we compared the correlation between C4 protein in neutrophils, classical monocytes, plasma, and the number of C4A gene copies. We determined the number of C4A genes using digital droplet PCR, C4 protein in neutrophils (15 patients/21 controls) and plasma (30 patients/38 controls) using Western blotting, and classical monocytes (30 patients/38 controls) using flow cytometry. We found a large positive correlation between the number of C4A gene copies and the amount of C4 protein only in neutrophils and only in the schizophrenia group (Spearman’s rho = 0.63, 95% BCa CI: 0.12 to 0.89, P = 0.012). Our results indicate a convergence of innate immunity mechanisms associated with schizophrenia. The involvement of innate immunity deserves further attention to determine whether it could be a target for therapy in schizophrenia.
- Open Access
- 30 March 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (14)
Cytotoxic T cell recognition of α-synuclein drives pathogenic immune responses in multiple system atrophy
Multiple system atrophy (MSA) is a progressive neurologic disease, known as an α-synucleinopathy. There are currently no effective disease-modifying therapies for MSA. While neuroinflammation is a hallmark of MSA, the contribution of adaptive immune mechanisms remains poorly understood. Here, we profiled peripheral and central T cell responses in patients with MSA, in comparison with Parkinson’s disease (PD) and healthy control cohorts, using single-cell transcriptomics, flow cytometry, and antigen-specific functional assays. We demonstrated that peripheral T cells from MSA patients are activated and skewed toward cytotoxic and inflammatory phenotypes. Single-cell transcriptomics further revealed clonal expansion of cytotoxic CD8 + T cells expressing GZMB , GNLY , and chemokine and integrin programs associated with brain homing. We also demonstrated that both CD4 + and CD8 + T cells from MSA patients recognize α-synuclein monomers and preformed fibrils in an HLA class I/II-dependent manner, driving proliferation, clonal expansion, and acquisition of cytotoxic features. Consistent with these peripheral responses, CD8 + T cell density was increased in the parietal cortex of postmortem MSA brain tissues, along with cytotoxic (GZMB + , GZMK + ) and proinflammatory (IFNγ + ) CD8 + T cells. Together, these findings demonstrate that cytotoxic T cells targeting α-synuclein are engaged in MSA, suggesting that their activity may contribute to neuroinflammation and disease progression, and highlighting this immune axis as a candidate therapeutic target for further investigation.
- 30 March 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (14)
Open AccessCytotoxic T cell recognition of α-synuclein drives pathogenic immune responses in multiple system atrophy
Multiple system atrophy (MSA) is a progressive neurologic disease, known as an α-synucleinopathy. There are currently no effective disease-modifying therapies for MSA. While neuroinflammation is a hallmark of MSA, the contribution of adaptive immune mechanisms remains poorly understood. Here, we profiled peripheral and central T cell responses in patients with MSA, in comparison with Parkinson’s disease (PD) and healthy control cohorts, using single-cell transcriptomics, flow cytometry, and antigen-specific functional assays. We demonstrated that peripheral T cells from MSA patients are activated and skewed toward cytotoxic and inflammatory phenotypes. Single-cell transcriptomics further revealed clonal expansion of cytotoxic CD8 + T cells expressing GZMB , GNLY , and chemokine and integrin programs associated with brain homing. We also demonstrated that both CD4 + and CD8 + T cells from MSA patients recognize α-synuclein monomers and preformed fibrils in an HLA class I/II-dependent manner, driving proliferation, clonal expansion, and acquisition of cytotoxic features. Consistent with these peripheral responses, CD8 + T cell density was increased in the parietal cortex of postmortem MSA brain tissues, along with cytotoxic (GZMB + , GZMK + ) and proinflammatory (IFNγ + ) CD8 + T cells. Together, these findings demonstrate that cytotoxic T cells targeting α-synuclein are engaged in MSA, suggesting that their activity may contribute to neuroinflammation and disease progression, and highlighting this immune axis as a candidate therapeutic target for further investigation.
- Top Cited PapersOpen Access
- 6 March 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (11)
Multiple molecular mimics in Epstein Barr Nuclear Antigen-1, and the pathogenesis of multiple sclerosis
The Epstein–Barr virus (EBV) infects greater than 95% of humans and is associated with initiating and perpetuating multiple sclerosis (MS). Antibody to Epstein–Barr Nuclear Antigen-1 (EBNA1) is present in nearly 100% of patients with MS before the development of clinical symptoms. Infection with EBV is necessary, but not sufficient, for causation of disease. Within the EBNA1 transcription factor is a stretch of 47 amino acids containing three regions with shared linear sequences of portions of three molecules, Glialcell adhesion molecule (CAM), alpha Crystallin-B, and Anoctamin-2. These cross-reactive linear sequences between EBNA1 and each of these three molecules are termed “molecular mimics.” Cross-reactive adaptive immunity to these three molecules mimicking regions of EBNA1 each play distinct roles in the pathogenesis of MS. Antibodies to each of these molecules greatly increase the chance of developing MS. Analysis of the cellular landscape of MS lesions reveals EBNA1 in B cells, glial cells, and neurons. Here, we provide commentary on recent publications on the molecular and cellular landscape of EBV infection in studies on the blood, cerebrospinal fluid, and brain specimens of individuals with MS. The published studies reveal perspectives on the pathology of MS in detail ranging from the atomic level using crystallography to multiplexed anatomical imaging of lesions in the brain.
- 6 March 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (11)
Top Cited PapersOpen AccessMultiple molecular mimics in Epstein Barr Nuclear Antigen-1, and the pathogenesis of multiple sclerosis
The Epstein–Barr virus (EBV) infects greater than 95% of humans and is associated with initiating and perpetuating multiple sclerosis (MS). Antibody to Epstein–Barr Nuclear Antigen-1 (EBNA1) is present in nearly 100% of patients with MS before the development of clinical symptoms. Infection with EBV is necessary, but not sufficient, for causation of disease. Within the EBNA1 transcription factor is a stretch of 47 amino acids containing three regions with shared linear sequences of portions of three molecules, Glialcell adhesion molecule (CAM), alpha Crystallin-B, and Anoctamin-2. These cross-reactive linear sequences between EBNA1 and each of these three molecules are termed “molecular mimics.” Cross-reactive adaptive immunity to these three molecules mimicking regions of EBNA1 each play distinct roles in the pathogenesis of MS. Antibodies to each of these molecules greatly increase the chance of developing MS. Analysis of the cellular landscape of MS lesions reveals EBNA1 in B cells, glial cells, and neurons. Here, we provide commentary on recent publications on the molecular and cellular landscape of EBV infection in studies on the blood, cerebrospinal fluid, and brain specimens of individuals with MS. The published studies reveal perspectives on the pathology of MS in detail ranging from the atomic level using crystallography to multiplexed anatomical imaging of lesions in the brain.
- Open Access
EBV reprograms autoreactive anti-CNS B cells as antigen presenting cells in multiple sclerosis
Summary paragraph: Multiple sclerosis (MS) is a chronic autoimmune disease targeting the central nervous system (CNS). MS develops almost exclusively in individuals previously infected with Epstein–Barr virus (EBV) 1 , yet the mechanisms linking EBV infection to MS pathogenesis remain incompletely defined. Here we characterized EBV-infected B cells in MS and demonstrated that EBV directly infects autoreactive anti-CNS antigen B cells and reprograms them into pro-inflammatory antigen-presenting cells (APCs). EBV⁺ B cells in MS were enriched within the CD27⁺CD21 low memory B-cell subset and exhibited upregulated B cell activation and APC transcriptional programs. Recombinant antibodies derived from MS blood and cerebrospinal fluid (CSF) EBV⁺ B cells bound brain tissue, and several cross-bound both MS-associated autoantigens and Epstein-Barr virus nuclear antigen-1 (EBNA1). In vitro , EBV⁺ B cells functioned as APCs that stimulated T peripheral helper cells, with associated activation of EBV⁻ anti-CNS antigen B cells. Collectively, these findings support a mechanistic framework in which EBV infects and transcriptionally reprograms autoreactive anti-CNS antigen B cells into APCs that drive pathogenic anti-CNS antigen T cell and EBV - B cell responses in MS.
Open AccessEBV reprograms autoreactive anti-CNS B cells as antigen presenting cells in multiple sclerosis
Summary paragraph: Multiple sclerosis (MS) is a chronic autoimmune disease targeting the central nervous system (CNS). MS develops almost exclusively in individuals previously infected with Epstein–Barr virus (EBV) 1 , yet the mechanisms linking EBV infection to MS pathogenesis remain incompletely defined. Here we characterized EBV-infected B cells in MS and demonstrated that EBV directly infects autoreactive anti-CNS antigen B cells and reprograms them into pro-inflammatory antigen-presenting cells (APCs). EBV⁺ B cells in MS were enriched within the CD27⁺CD21 low memory B-cell subset and exhibited upregulated B cell activation and APC transcriptional programs. Recombinant antibodies derived from MS blood and cerebrospinal fluid (CSF) EBV⁺ B cells bound brain tissue, and several cross-bound both MS-associated autoantigens and Epstein-Barr virus nuclear antigen-1 (EBNA1). In vitro , EBV⁺ B cells functioned as APCs that stimulated T peripheral helper cells, with associated activation of EBV⁻ anti-CNS antigen B cells. Collectively, these findings support a mechanistic framework in which EBV infects and transcriptionally reprograms autoreactive anti-CNS antigen B cells into APCs that drive pathogenic anti-CNS antigen T cell and EBV - B cell responses in MS.
- 14 January 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (4) , 359-360
Targeting Epstein–Barr virus is a viable therapeutic strategy in multiple sclerosis: Yes
- 14 January 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (4) , 359-360
Targeting Epstein–Barr virus is a viable therapeutic strategy in multiple sclerosis: Yes
- 1 January 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (1) , e200517
Sjögren Syndrome Candidate Autoantigen AQP5 Triggers AQP4 CNS Autoimmunity Through Self-Antigen Mimicry
Aquaporin (AQP)-4 (AQP4)-seropositive neuromyelitis optica (NMO) frequently coexists with rheumatologic autoimmune conditions, including Sjögren syndrome and systemic lupus erythematosus, 2 conditions that share a common HLA-DRB1 (HLA-DRB1*03:01) association with NMO. AQP4 is a member of a family of ubiquitously expressed water channels. Its immunodominant pathogenic T-cell epitope, which binds MHC II with exceptionally high affinity, is homologous to sequences in other AQPs, including AQP5, a candidate target autoantigen in Sjögren syndrome. Thus, we hypothesized that self-antigen molecular mimicry exists between AQPs and contributes to autoimmunity. Previously, we examined binding of AQP4 T-cell epitopes to MHC II (I-Ab) by biochemical assays; we now evaluate interaction of I-Ab and AQPs by molecular modeling. T cells from mice immunized with the immunodominant AQP4 epitope or its homologous AQP5 sequence were examined for proliferation and cross-recognition between AQPs. T-cell receptor (TCR) engagement of individual T cells with AQP-MHC II complexes was examined using AQP4 and AQP5 peptide/MHC II tetramers. The pathogenic potential of AQP4-primed and AQP5-primed T cells was examined by T-cell adoptive transfer into naïve mice. The immunodominant AQP4 T-cell epitope was predicted to make optimal contacts within the pockets of the MHC II antigen-binding cleft. Like AQP4, the corresponding homologous AQP5 amino acid sequence was predicted to bind MHC II, albeit with modest affinity. In a reciprocal manner, T cells were detected that proliferated to both AQP4 and AQP5. Multi-tetramer analysis of individual T cells demonstrated that the same TCR could engage both AQP4 and AQP5. T cells from mice immunized with AQP4 or AQP5 caused paralysis and CNS inflammation in recipient mice, but not in AQP4-deficient mice, demonstrating that AQP4 expression is obligately required in this model of aquaporin CNS autoimmunity. T cells can express TCRs that recognize multiple AQPs. Autoimmunity can be initiated through molecular mimicry between distinct self-antigens such as AQP4 and AQP5 that are expressed in separate organs. These findings suggest that T-cell self-antigen mimicry may contribute to coexistence of NMO with other autoimmune conditions, such as Sjögren syndrome.
- 1 January 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (1) , e200517
Sjögren Syndrome Candidate Autoantigen AQP5 Triggers AQP4 CNS Autoimmunity Through Self-Antigen Mimicry
Aquaporin (AQP)-4 (AQP4)-seropositive neuromyelitis optica (NMO) frequently coexists with rheumatologic autoimmune conditions, including Sjögren syndrome and systemic lupus erythematosus, 2 conditions that share a common HLA-DRB1 (HLA-DRB1*03:01) association with NMO. AQP4 is a member of a family of ubiquitously expressed water channels. Its immunodominant pathogenic T-cell epitope, which binds MHC II with exceptionally high affinity, is homologous to sequences in other AQPs, including AQP5, a candidate target autoantigen in Sjögren syndrome. Thus, we hypothesized that self-antigen molecular mimicry exists between AQPs and contributes to autoimmunity. Previously, we examined binding of AQP4 T-cell epitopes to MHC II (I-Ab) by biochemical assays; we now evaluate interaction of I-Ab and AQPs by molecular modeling. T cells from mice immunized with the immunodominant AQP4 epitope or its homologous AQP5 sequence were examined for proliferation and cross-recognition between AQPs. T-cell receptor (TCR) engagement of individual T cells with AQP-MHC II complexes was examined using AQP4 and AQP5 peptide/MHC II tetramers. The pathogenic potential of AQP4-primed and AQP5-primed T cells was examined by T-cell adoptive transfer into naïve mice. The immunodominant AQP4 T-cell epitope was predicted to make optimal contacts within the pockets of the MHC II antigen-binding cleft. Like AQP4, the corresponding homologous AQP5 amino acid sequence was predicted to bind MHC II, albeit with modest affinity. In a reciprocal manner, T cells were detected that proliferated to both AQP4 and AQP5. Multi-tetramer analysis of individual T cells demonstrated that the same TCR could engage both AQP4 and AQP5. T cells from mice immunized with AQP4 or AQP5 caused paralysis and CNS inflammation in recipient mice, but not in AQP4-deficient mice, demonstrating that AQP4 expression is obligately required in this model of aquaporin CNS autoimmunity. T cells can express TCRs that recognize multiple AQPs. Autoimmunity can be initiated through molecular mimicry between distinct self-antigens such as AQP4 and AQP5 that are expressed in separate organs. These findings suggest that T-cell self-antigen mimicry may contribute to coexistence of NMO with other autoimmune conditions, such as Sjögren syndrome.